The Role of Some Chemokines from the CXC Subfamily in a Mouse Model of Diabetic Neuropathy

Figure 4

Effects of CXCL1, CXCL5, CXCL9, or CXCL12 administration on the nociceptive threshold. The influence of a single intrathecal administration of 10 ng, 100 ng, or 500 ng/5 μL of CXCL1 (a), CXCL5 (b), CXCL9 (c), or CXCL12 (d) on the nociceptive threshold was evaluated using a tail-flick test. The measurements were taken 1, 4, and 24 hours after chemokine administration. The data are presented as fold change in the control (naïve) ± S.E.M. (6–16 mice per group). Intergroup differences were analyzed by an ANOVA and Bonferroni’s Multiple Comparison Test. , , and indicate a significant difference; the statistical analysis was performed versus control (naïve) mice.

(a)

(b)

(c)

(d)